Key Insights

Highlights

Success Rate

100% trial completion (above average)

Published Results

13 trials with published results (41%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 32 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

41%

13 trials in Phase 3/4

Results Transparency

52%

13 of 25 completed with results

Key Signals

13 with results100% success

Data Visualizations

Phase Distribution

26Total
Not Applicable (2)
Early P 1 (1)
P 1 (7)
P 2 (3)
P 3 (9)
P 4 (4)

Trial Status

Completed25
Unknown6
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 25 completed trials

Clinical Trials (32)

Showing 20 of 20 trials
NCT02453048Phase 1Completed

Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine

NCT05091619Phase 3Active Not RecruitingPrimary

A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed

NCT04678271Not ApplicableCompleted

Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increase Maternal Vaccine Uptake

NCT03942406Phase 2Completed

Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults

NCT03463577CompletedPrimary

The Safety of Boostrix Following Routine Immunization of Pregnant Women

NCT01439165Phase 4Completed

Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose

NCT03147898CompletedPrimary

Observational Study Describing the Immune Profile Induced By Pertussis Vaccines

NCT03578120CompletedPrimary

Immunising Mums Against Pertussis 3

NCT02587520Phase 1Completed

Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects

NCT03973905CompletedPrimary

Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants <2 Months Old in the United States

NCT03035370Phase 1CompletedPrimary

Viaskin Pertussis Vaccine Trial

NCT03751514Not ApplicableUnknownPrimary

Bordetella Pertussis Colonisation Challenge Study

NCT04238975Phase 2Unknown

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults

NCT02301702Phase 2Completed

Maternal Tdap Immunization in Guatemala

NCT04036526Phase 1UnknownPrimary

A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine

NCT03137927Phase 1CompletedPrimary

A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine

NCT00337428Phase 3Completed

Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)

NCT02813486Phase 1Unknown

Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine

NCT02771782Phase 4UnknownPrimary

Influence of BCG on TDaP-IPV Vaccination

NCT01529645Phase 1Completed

Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years

Scroll to load more

Research Network

Activity Timeline